Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risk of venous thromboembolism and safety of newly diagnosed multiple myeloma patients receiving carfilzomib lenalidomide dexamethasone with or without rivaroxaban prophylaxis

Next Previous
Search
Trial Profile

Risk of venous thromboembolism and safety of newly diagnosed multiple myeloma patients receiving carfilzomib lenalidomide dexamethasone with or without rivaroxaban prophylaxis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aspirin (Primary) ; Bortezomib (Primary) ; Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Rivaroxaban (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions

    • Most Recent Events

    • 01 Jan 2022 Results published in the British Journal of Haematology
    • 11 Dec 2019 New trial record
    • 10 Dec 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top